2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.
作者信息
Graham Jeffrey, Ahmad Ardalan E, Basappa Naveen S, Bernhard Jean-Christophe, Bhindi Bimal, Bossé Dominick, Breau Rodney H, Canil Christina M, Castonguay Vincent, Finelli Antonio, Heng Daniel Y C, Inman Brant A, Kollmannsberger Christian, Lalani Aly-Khan A, Lavallée Luke T, Msaouel Pavlos, Prendeville Susan, Soleimani Maryam, Tanguay Simon, Wood Lori, Richard Patrick O
机构信息
Department of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB, Canada.
Division of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
出版信息
Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041.
Abstract
摘要
相似文献
1
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.2024年美国泌尿外科学会-韩国肾脏研究与护理网络专家报告：非透明细胞肾细胞癌的管理
Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041.
2
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.加拿大肾癌研究网络（KCRNC）关于减瘤性肾切除术对转移性肾细胞癌患者作用的共识声明。
Can Urol Assoc J. 2019 Jun;13(6):166-174. doi: 10.5489/cuaj.5786.
3
Comparison of Renal Cell Carcinoma Surveillance Guidelines: Competing Trade-Offs.比较肾癌监测指南：权衡取舍。
J Urol. 2016 Jun;195(6):1664-70. doi: 10.1016/j.juro.2015.12.094. Epub 2016 Jan 14.
4
2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board.2023年更新——加拿大泌尿外科协会指南：囊性肾病变的管理 在最初发布（2017年3月）之前，本指南经过了加拿大泌尿外科协会指南委员会、广大加拿大泌尿外科协会成员以及加拿大泌尿外科协会执行委员会的审查。2023年的更新内容已获加拿大泌尿外科协会指南委员会和加拿大泌尿外科协会执行委员会批准。
Can Urol Assoc J. 2023 Jun;17(6):162-174. doi: 10.5489/cuaj.8389.
5
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer.加拿大肾癌研究网络（KCRNC）关于肾肿物活检在肾癌管理中作用的共识声明。
Can Urol Assoc J. 2019 Dec;13(12):377-383. doi: 10.5489/cuaj.6176. Epub 2019 Sep 17.
6
Calciphylaxis: Beyond CKD-MBD.钙敏感受体病：超越慢性肾脏病-矿物质和骨异常
Nefrologia. 2017 Sep-Oct;37(5):501-507. doi: 10.1016/j.nefro.2017.02.006. Epub 2017 Apr 5.
7
2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma.2024年美国泌尿外科学会-全球泌尿外科肿瘤学会专家报告：不可切除的局部晚期和转移性尿路上皮癌的管理
Can Urol Assoc J. 2024 Dec;18(12):379-390. doi: 10.5489/cuaj.8946.
8
Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy.钙化防御相关皮肤沉积物在钙化性尿毒症性小动脉病患者中的定位、形态特征和化学成分。
JAMA Dermatol. 2019 Jul 1;155(7):789-796. doi: 10.1001/jamadermatol.2019.0381.
9
Multifaceted approach to a rare clinical case of calciphylaxis in a renal transplant recipient.肾移植受者罕见钙化防御临床病例的多方面处理方法。
G Ital Nefrol. 2019 Sep 24;36(5):2019-vol5.
10
Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study.法国慢性肾病患者中钙敏性坏死的流行病学、危险因素、治疗及生存率：一项病例对照研究
BMC Nephrol. 2020 Feb 26;21(1):63. doi: 10.1186/s12882-020-01722-y.
本文引用的文献
1
Frequency and clinicopathologic features of renal low-grade oncocytic tumour and eosinophilic vacuolated tumour: reclassification of 605 eosinophilic tumours including patients managed with active surveillance.肾低度嗜酸细胞瘤和嗜酸性空泡状肿瘤的发病率及临床病理特征：对605例嗜酸性肿瘤进行重新分类，包括接受主动监测的患者。
J Clin Pathol. 2024 Jul 20. doi: 10.1136/jcp-2024-209711.
2
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.肾髓质癌患者的临床特征、治疗及预后：135例患者的单中心回顾性分析
Eur Urol Oncol. 2025 Apr;8(2):315-323. doi: 10.1016/j.euo.2024.07.002. Epub 2024 Jul 15.
3
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.辅助依维莫司治疗完全切除的、高风险肾透明细胞癌患者：来自 III 期安慰剂对照 SWOG S0931（EVEREST）试验的结果。
Eur Urol. 2024 Sep;86(3):258-264. doi: 10.1016/j.eururo.2024.05.012. Epub 2024 May 29.
4
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌患者：来自一项 2 期试验的更新结果。
Eur Urol. 2024 Aug;86(2):90-94. doi: 10.1016/j.eururo.2024.04.025. Epub 2024 May 22.
5
Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.肾细胞癌的变异组织学：新的生物学理解带来治疗进展。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438642. doi: 10.1200/EDBK_438642.
6
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.帕博利珠单抗辅助治疗用于肾细胞癌的总生存期。
N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695.
7
Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features.肾细胞癌患者的致病性种系突变全景及其相关临床病理特征。
JCO Precis Oncol. 2023 Sep;7:e2300168. doi: 10.1200/PO.23.00168.
8
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.真实世界中伴有或不伴有肉瘤样特征的转移性肾细胞癌患者接受一线系统治疗的临床结局评估。
Eur Urol Oncol. 2024 Jun;7(3):570-580. doi: 10.1016/j.euo.2023.11.016. Epub 2023 Dec 13.
9
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?免疫检查点抑制剂联合治疗后延期减瘤性肾切除术的适应症和结果：在无疾病证据的患者中能否停止全身治疗？
Eur Urol Open Sci. 2023 Aug 4;55:15-22. doi: 10.1016/j.euros.2023.07.002. eCollection 2023 Sep.
10
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.帕博利珠单抗治疗晚期肾髓质癌疗效与安全性的II期临床试验
Cancers (Basel). 2023 Jul 27;15(15):3806. doi: 10.3390/cancers15153806.
Zotero 插件